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Abstract
Adverse maternal environments can lead to increased fetal exposure to maternal cortisol, which can cause infant
neurobehavioral deficits. The placenta regulates fetal cortisol exposure and response, and placental DNA methylation can
influence this function. FK506 binding protein (FKBP5) is a negative regulator of cortisol response, FKBP5 methylation has
been linked to brain morphology and mental disorder risk, and genetic variation of FKBP5 was associated with post-
traumatic stress disorder in adults. We hypothesized that placental FKBP5 methylation and genetic variation contribute to
gene expression control, and are associated with infant neurodevelopmental outcomes assessed using the Neonatal
Intensive Care Unit (NICU) Network Neurobehavioral Scales (NNNS). In 509 infants enrolled in the Rhode Island Child Health
Study, placental FKBP5 methylation was measured at intron 7 using quantitative bisulfite pyrosequencing. Placental FKBP5
mRNA was measured in a subset of 61 infants by quantitative PCR, and the SNP rs1360780 was genotyped using a
quantitative allelic discrimination assay. Relationships between methylation, expression and NNNS scores were examined
using linear models adjusted for confounding variables, then logistic models were created to determine the influence of
methylation on membership in high risk groups of infants. FKBP5 methylation was negatively associated with expression
(P= 0.08, r =20.22); infants with the TT genotype had higher expression than individuals with CC and CT genotypes
(P= 0.06), and those with CC genotype displayed a negative relationship between methylation and expression (P= 0.06,
r =20.43). Infants in the highest quartile of FKBP5 methylation had increased risk of NNNS high arousal compared to infants
in the lowest quartile (OR 2.22, CI 1.07–4.61). TT genotype infants had increased odds of high NNNS stress abstinence (OR
1.98, CI 0.92–4.26). Placental FKBP5 methylation reduces expression in a genotype specific fashion, and genetic variation
supersedes this effect. These genetic and epigenetic differences in expression may alter the placenta’s ability to modulate
cortisol response and exposure, leading to altered neurobehavioral outcomes.
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Introduction
The developmental origins of health and disease model has
highlighted the significance of the fetal environment on neurolog-
ical and behavioral outcomes [1]. The fetus can be exposed to
maternal cortisol in circulation, and excessive cortisol exposure,
associated with maternal adversity, is also associated with
neurological and developmental problems [2]. Prenatal cortisol
exposure predicts infant cortisol response to acute stress [3], and
cortisol reactivity is associated with infant behavioral reactivity [4].
In humans, pregnancy stress is associated with increased incidence
of affective disorders, including attention deficient disorder [5,6],
anxiety, and lowered cognitive and language abilities [7]. These
associations are likely mediated by altered fetal cortisol exposure
and reactivity, but the molecular mechanisms underlying this
relationship remain unclear.
The placenta, a central regulator of fetal development, is a
plastic organ that can respond to maternal signals and contribute
to developmental outcomes by altering the environment of the
developing fetus [8]. Alterations to placental function can occur
through epigenetic mechanisms, including DNA methylation,
which in regulatory regions alters gene transcription or transcrip-
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tion potential [9]. Placental methylation patterns influence global
placental gene expression, and thus function, during crucial
developmental periods [10]. Patterns of placental DNA methyl-
ation are dynamic, can be modified by various factors in the
maternal environment [11–15], and can influence infant neuro-
logical, behavioral and cognitive outcomes. Methylation of cortisol
response genes 11-beta hydroxysteroid dehydrogenase type 2
(HSD11B2) and the glucocorticoid receptor (NR3C1) have been
associated with infant clinical and neurobehavioral outcomes,
quantified through the Neonatal Intensive Care Unit (NICU)
Network Neurobehavioral Scales (NNNS), a validated assessment
to quantify newborn and infant neurobehavior [11,16,17].
FKBP5 (FK506 binding protein) decreases the binding of
cortisol to its receptor and impedes nuclear translocation [18],
leading to reduced cortisol response. FKBP5 methylation within a
regulatory region of intron 7 has been associated with neurological
outcomes [19,20]. Intron 7 has been shown to bind to the
transcriptional start site of FKBP5 using chromatin confirmation
capture, and methylation alters FKBP5 induction [20]. Gluco-
corticoid exposure has been associated with alterations to FKBP5
intronic methylation in the hippocampus and blood of mice [21].
In a human hippocampal progenitor cell line, cortisol induced de-
methylation of this regulatory region within intron 7 during critical
periods of cellular differentiation and proliferation [20], which
may be particularly relevant during fetal development, when cells
are rapidly proliferating. FKBP5 polymorphisms are also associ-
ated with altered induction of mRNA, changes to hippocampal
size [20,22], as well as diseases associated with alterations in the
hypothalamic-pituitary-adrenal (HPA) axis, such as post-traumatic
stress disorder (PTSD) [23–27]. The SNP rs1360780 is located
near a functional response element within intron 2, and is strongly
associated with diseases involving dysregulation of the HPA axis
[28–30]. FKBP5 expression is induced in a genotype specific
manner, as the T allele binds to the transcriptional start site to
enhance transcription [31]. The CT and TT genotype are
associated with increased cortisol activity and altered physiological
stress regulation in infants [32]. Epidemiological evidence suggests
that a combination of genetic polymorphisms and cortisol induced
FKBP5 DNA methylation are associated with HPA axis related
disorders.
FKBP5 is expressed within the placenta [33], but its functional
relevance and potential for epigenetic control remain unknown.
Since the placenta regulates fetal exposure and response to
maternal cortisol, placental FKBP5 could potentially alter fetal
development, particularly neurobehavioral development. The
aims of this study were to determine the relationship between
placental FKBP5 methylation, genetic variation, and placental
gene expression, and to determine if differential methylation and
genotype associated with infant neurodevelopmental outcomes
related to dysregulation of the HPA axis. In this study, we show
that FKBP5 intron 7 methylation reduces placental gene
expression, genetic variation at rs1360780 influences placental
gene expression, higher FKBP5 intron 7 methylation is associated
with increased risk of high infant arousal, and the TT genotype of
rs1360780 is associated with high infant stress abstinence as
quantified using the NNNS, a series of validated, quantitative
measures of infant neurobehavior.
Results
Demographic characteristics of the 509 infants in this study are
shown in Table 1. All infants were .37 weeks gestation, with a
mean gestational age of 39.01 weeks. There was a nearly identical
proportion of females compared to males (50.7% vs. 49.3%). This
study oversampled for large for gestational age (LGA, .90th BW
percentile, 25.9%) and small for gestational age (SGA, ,10th BW
percentile, 20.0%) infants. All infants were genotyped for the SNP
rs1360780, and the minor genotype frequency (TT) was 0.07. The
distribution of genotypes is in Hardy-Weinberg equilibrium, and is
similar to the expected frequency within the CEU population
according to dbSNP.
We quantified methylation of 2 CpGs through pyrosequencing
of placenta samples in 509 infants, and methylation of these 2
CpGs was well correlated (Cor= 0.35, P = 4.44610216) and and
as expected each was correlated to the mean of the 2 sites
(Correlation of CpG 1 with mean: cor = 0.77, P= 2.2610216;
correlation of CpG 2 with mean: cor = 0.86, P= 2.2610216).
Thus, to reduce multiple comparisons, the mean methylation of
these sites was used for further analysis. In this population, the
mean methylation of the CpGs examined was 87.15% (range
76.15%–98.82%, SD 3.44%), and this data was normally
distributed. The relationship between methylation and infant
clinical outcomes was examined and shown in Table 1. There
were subtle, statistically significant differences in methylation
based on infant birth weight category, and infant gender. We
observed that SGA infants had slightly higher methylation (87.9%)
than AGA and LGA infants (87.06% and 86.74%, respectively)
(P=0.03, ANOVA). Males had higher methylation than females
(87.47% compared to 86.82%, P=0.03). Infants with the CC and
CT genotypes had lower methylation than the TT genotype (CC
and CT mean= 87.01, TT mean= 88.25, P=0.03, T-Test),
although this difference was attenuated when individuals are
stratified by individual genotype (P=0.09, ANOVA).
FKBP5 gene expression was quantified in a subset of 63
placentas, 21 randomly selected from each genotype. After
assessing ddPCR results for quality control, the N was reduced
to 61 (19 CC, 21 CT, 21 TT genotypes). Gene expression was
calculated as the counts of the FKBP5 divided by the counts of
SDHA as a housekeeping gene. To determine the association
between expression and genotype, mean methylation of CC was
set as the reference genotype, and with the mean of CT and TT
genotypes normalized to this value. In Figure 1 A, comparing
across the three genotypes suggested differences in expression by
genotype (P= 0.07 ANOVA), with statistically significant differ-
ences between the TT and CT genotypes (P = 0.05, Tukey’s test),
and no differences between the CT and CC genotype (P = 0.43,
Tukey’s test). Among all genotypes combined, gene expression was
negatively correlated with methylation, although this did not attain
statistical significance at the P=0.05 level. (Cor =20.22,
P=0.08, Figure 1B). Based on previous evidence of genotype
specific associations between methylation and expression [20], we
stratified by rs1360780 genotype (Figure1 C–E), which revealed
that the C allele appeared to be driving this relationship. The CC
genotype showed a strong correlation between methylation and
expression that approached but did not obtain statistical signifi-
cance at the P=0.05 level (Cor =20.43, P=0.06, Figure 1C),
whereas there was no correlation between methylation and
expression observed with the CT genotype (Cor =20.17,
P=0.46, Figure 1D), or with the TT genotype (Cor =20.10,
P=0.67 Figure 1E).
We fit a series of 6 linear regression models to determine the
role of FKBP5 methylation and the rs1360780 genotype on infant
neurobehavioral outcomes. We focused on the 6 infant NNNS
outcomes (habituation, attention, stress-abstinence, quality of
movement, handling, and arousal) found to be most sensitive in
prior studies [34,35]. Each of the models was adjusted for infant
birth weight group, maternal age, sex, and rs1360780 genotype,
with CC as the referent genotype (Table 2). We observed a
FKBP5 Placental Variation and Infant Neurobehavior
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significant positive relationship between FKBP5 methylation and
infant arousal in the unadjusted model (Estimate = 0.02, P=0.03),
which was strengthened in the adjusted model (Estimate = 0.03,
P=0.005). Infants with the TT genotype of rs1360780 had
increased stress abstinence scores compared to infants in the CC
genotype (Estimate = 0.03, P=0.03), and this relationship was
maintained in the adjusted model (Estimate = 0.02, P=0.04).
Infants with the CT genotype did not display increased stress
abstinence compared to infants with the CC genotype in the
adjusted or unadjusted models.
To improve interpretability, infants were dichotomized into
high vs. normal arousal and stress abstinence groups using
normative scales by Fink et al [36]. Infants defined as high
arousal (scores .5.14), represented 16.3% of our population
(N= 83). Infants defined as high stress abstinence (scores .0.2)
represented 38.3% of our cohort (N=195). As we observed
differential effects of methylation on expression by genotype, we
sought to control for genotype in our models of methylation and
NNNS outcomes. Thus we fit logistic regression models controlled
for infant birth weight group, maternal age, sex, and rs1360780
genotype (Table 3). We stratified methylation into quartiles
(Quartile 1: 76.15%–,85.06%, Quartile 2: 85.06%–,87.28%,
Quartile 3: 87.28%–,89.23%, Quartile 4: 89.2%–98.82%), and
analyzed associations with methylation as a categorical variable.
Infants with methylation in the highest quartile demonstrated a
1.83 fold increased odds of being classified as high arousal (95% CI
0.91–3.68) compared to infants in the lowest quartile in an
unadjusted model, and the risk became greater in the adjusted
model (OR 2.22, 95% CI 1.07–4.61). Additionally, we observed
that infant birth weight category was independently associated
with infant arousal group, with SGA infants having a lower odds of
high arousal in the adjusted model compared to AGA infants (OR
0.44, CI 0.20, 0.96), and LGA infants having a higher odds of high
arousal than AGA infants (OR 1.76, CI 1.01, 3.04). Males had
lower odds of high arousal compared to females (OR 0.52, CI
0.31, 0.85). We observed no interaction between gender and birth
weight on the relationship observed between methylation and
infant arousal (data not shown). Maternal age and genotype did
not significantly influence membership in this group.
There was no statistically significant association between high
stress abstinence and FKBP5 methylation quartiles (see table 3).
Infants with the TT genotype had borderline significantly higher
odds of being in the high stress abstinence group (OR 1.98, CI
0.92–4.26) compared to CC infants in the adjusted model. Infants
with the CT genotype did not have statistically higher odds of
increased stress abstinence compared to CC infants (OR 1.1, CI
0.73–1.65). Maternal age, infant birth weight group, and gender
appeared to have no effect on membership in the high stress
abstinence group in the adjusted model.
Discussion
We analyzed placental methylation of the functionally relevant
intron 7 of FKBP5, a negative regulator of cortisol response, and
we observed that infants with higher methylation were at increased
risk of exhibiting high arousal NNNS scores. We also found that
Table 1. Infant Clinical and Demographic Information and relation to FKBP5 methylation.
N % Mean Std Dev. Mean FKBP5 Methylation P
Maternal age 509 29.32 5.53
Pregnancy tobacco use 0.35
Yes 22 4.3 87.89
No 481 94.5 87.12
NA 6 1.2
Birth weight grams) 509 3489 682.54 0.01
Gestational age (weeks) 509 39.01 0.95 0.32
Birth weight Category 0.03
LGA 132 25.9 86.74
AGA 275 54 87.06
SGA 102 20 87.9
Gender 0.03
Female 258 50.7 86.82
Male 251 49.3 87.47
rs1360780 0.09
CC 231 45.4 86.9
CT 235 46.2 87.11
TT 35 6.9 88.25
NA 8 1.6
doi:10.1371/journal.pone.0104913.t001
FKBP5 Placental Variation and Infant Neurobehavior
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infants with the minor genotype of rs1360780 were more likely to
exhibit high stress abstinence independently of intron 7 methyl-
ation. The placenta modulates fetal exposure to maternal cortisol,
and FKBP5 is expressed within the placenta [33], but its role in
the regulation of cortisol response within the placenta remains
unknown. This study is the first to examine the consequences of
genetic and epigenetic variation on placental gene expression and
infant neurobehavioral outcomes.
Prior work has demonstrated that there is a complicated control
of FKBP5 expression based on interactions between various
intragenic regions with the transcriptional start site (TSS) [20].
Chromatin confirmation capture uses a series of cross linking and
restriction digests to identify three dimensional spatial relationships
within genes; specifically where different parts of the DNA interact
[37]. Chromatin conformation assays have revealed that intron 7
binds to the TSS, inducing transcription, and that DNA
methylation within intron 7 may inhibit this binding, resulting in
reduced expression [20]. Similarly, intron 2 interacts with the TSS
in an allele specific manner, enhancing expression [20]. We have
demonstrated higher placental expression of FKBP5 from infants
homozygous for the T allele compared to the heterozygotes and
homozygous C infants. We also demonstrated that methylation of
intron 7, as expected, was negatively correlated with expression,
but only amongst those newborns with the CC genotype. The
relationship between methylation and expression is not observed
in individuals with the TT and CT genotype, suggesting that the T
allele is also influencing FKBP5 expression, resulting in increased
expression of FKBP5 and a loss of relationship between
Figure 1. Methylation and Genotype are associated with FKBP5 Expression. Gene expression results were quantified in a subset (N= 61) of
all placentas sequenced A.Gene expression as quantified as FKBP5/SDHA counts stratified by genotype, divided by the mean value of the average of
the CC group (P=0.07, ANOVA, Tukey test CT vs. CC, P=0.53. CC vs TT P=0.41, TT vs CT P=0.05) B. Correlation of FKBP5/SDHA counts vs. FKBP5
Intron 7 Methylation (r =20.22, P= 0.08). C–E. Correlation of FKBP5/SHDA counts vs. FKBP5 Intron 7 methylation stratified by genotype.*P#0.1
** = P#0.05.
doi:10.1371/journal.pone.0104913.g001
FKBP5 Placental Variation and Infant Neurobehavior
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methylation and expression. These results are consistent with the
model proposed by Klengel et al [20], suggesting that the effect of
the T allele in intron 2 is dominant over the effect of methylation
at intron 7.
In our study, infants with the highest quartile of methylation of
FKBP5 intron 7 were over twice as likely to have NNNS arousal
scores in the highest 5th percentile compared to infants in the
lowest quartile of methylation. Newborn arousal is a behavioral
measure reflective of the infant’s state and motor activity during
the examination [38]; infants in the high arousal group would
display increased fussiness, more spontaneous movements, and
those with high arousal scores demonstrated higher risk scores in
subsequent prenatal screening using the Hobel and Verma Scales
[36]. Infants with the highest levels of methylation would
experience reduced FKBP5 expression, resulting in increased
cortisol activation of glucocorticoid receptors targets within the
placenta, which can influence activation of the glucorticoid
response pathway in the developing infant. Previous studies of
FKBP5 have observed associations with post-traumatic stress
disorders [24,26], and PTSD is characterized by hypervigilance
and hyperarousal. Thus, it appears that alterations to FKBP5 and
altered cortisol response influence behavior in a manner promot-
ing a hypervigilant response. Individuals with higher FKBP5
methylation in utero thus may have an over-active cortisol
response pathway at the time of birth, and may be predisposed
to develop disorders related to elevated HPA axis activity, such as
post-traumatic stress disorder or anxiety.
We also observed a relationship between the rs1360780
genotype and risk of membership in the highest 5th percentile of
stress abstinence. The stress abstinence summary score is a
measure of signs of physiological stress exhibited by the infant
[38], and infants in the highest 5th percentile as measured by Fink
et al [38] showed signs of stress or abstinence on at least 11 of the
49 stress abstinence signs assessed. High levels of stress abstinence
are generally associated with prenatal risk factors such as maternal
tobacco use [39], drug exposure [38] or labor complications [36].
We found that infants that possessed the TT genotype had
increased odds of membership in this group, and 51% of the
Table 2. Linear regression model of FKBP5 methylation, rs1360780 Genotype and NNNS outcomes.
Unadjusted Adjusted*
Estimate Std.Error P Estimate Std.Error P
Habituation
Methylation 20.03 0.02 0.21 20.04 0.02 0.12
CC ref. ref.
CT 0.24 0.17 0.15 0.23 0.17 0.18
TT 0.55 0.33 0.10 0.64 0.33 0.05
Attention
Methylation 0.01 0.02 0.43 0.01 0.02 0.44
CC ref. ref.
CT 0.06 0.13 0.64 0.04 0.13 0.78
TT 0.34 0.25 0.18 0.37 0.26 0.16
Handling
Methylation 0.00 0.00 0.55 0.00 0.00 0.53
CC ref. ref.
CT 0.03 0.02 0.16 0.03 0.02 0.15
TT 0.04 0.04 0.41 0.03 0.04 0.45
Quality of movement
Methylation 0.00 0.01 0.73 0.00 0.01 0.60
CC ref. ref.
CT 20.01 0.06 0.81 20.01 0.06 0.91
TT 20.16 0.12 0.18 20.15 0.12 0.21
Arousal
Methylation 0.02 0.01 0.03 0.03 0.01 0.005
CC ref. ref.
CT 20.02 0.07 0.81 20.01 0.07 0.84
TT 0.17 0.15 0.23 0.15 0.14 0.29
Stress abstinence
Methylation 0.00 0.00 0.17 0.00 0.00 0.19
CC ref. ref.
CT 0.00 0.01 0.83 0.00 0.01 0.75
TT 0.03 0.01 0.03 0.02 0.01 0.04
*Also adjusted for birth weight group, maternal age, gender and random effect of conversion plate.
doi:10.1371/journal.pone.0104913.t002
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infants classified as high stress abstinence possessed the TT
genotype; a much higher proportion than the CC and CT
genotypes. We note that this relationship did not reach statistical
significance, likely due to the low prevalence of the TT genotype
(6.9%). We showed that infants possessing the TT genotype have
higher expression of FKBP5 in the placenta, and we hypothesize
that this may reduce the activation of other glucocorticoid
response elements (such has HSD11B2), which may result in
increased fetal exposure to maternal cortisol. More detailed
analyses of the relationship of DNA methylation and expression
across the family of genes involved in cortisol regulation is
warranted.
We assume that infants with the TT genotype likely have higher
expression in other tissues throughout gestation, including the
brain, as the genotype would be constant in all tissues, and as we
have shown, appears to supersede methylation in driving
expression. Interestingly, the TT genotype has been associated
with heightened cortisol reactivity in infants [32] as well as adults
[28]. This effect is thought to reflect disruption of the negative
feedback loop over time due to altered homeostatic balance of
FKBP5 as a negative regulator, resulting in impaired recovery
from stressful situations [32]. Such a model is consistent with our
observed increased signs of stress abstinence, which suggest
impaired recovery from the stresses of the prenatal period and/
or delivery. Thus, these infants, who were born with elevated
expression of FKBP5 due to their genotype and already showed
elevated stress abstinence at the time of birth, may also be
predisposed to diseases associated with dysregulation of the HPA
axis. More follow up work is needed to connect our observed
associations of NNNS outcomes with later life psychological
distress, as well as the interaction with other regulators of
glucocorticoid response.
FKBP5 placental methylation is not a single predictor of infant
cortisol response, and we have a limited understanding of the
contribution of this methylation with other factors that can
influence infant neurobehavior; specifically infant gender and
infant birth weight, as well as methylation of other genes involved
in cortisol response, including HSD11B and NR3C1[11,16,17].
There are sexual dimorphisms in the onset and characteristics of
many behavioral disorders, which may be attributed to differential
DNA methylation in the placenta [40]. We observed that although
male infants had very slightly higher FKBP5 methylation than
females, they were independently less likely to be classified as high
arousal in our adjusted logistic model. Sex appears to have an
influence on neurobehavioral outcomes that is independent of
methylation within this population. The difference in methylation
between sexes suggests that sex hormones or sex-differentiating
factors may alter the mechanisms by which methylation patterns
are set in the placenta at specific regions, and more work is needed
to explore potential interactions between sex specific epigenetic
patterning and neurobehavioral outcomes. Birth weight can
broadly represent the quality of the intrauterine environment,
and both LGA [41]and SGA [42] infants exhibit increased risk of
neurological and cognitive deficits. We observed that although
SGA infants had slightly higher methylation of the FKBP5 intron
7 than LGA infants, they had decreased odds of being high arousal
compared to AGA infants, while LGA infants were more likely to
be classified as high arousal, controlled for methylation status.
Both FKBP5 placental methylation and birth weight appear to
contribute independently to risk of high infant arousal, although
FKBP5 methylation is a stronger predictor than infant birth
weight alone. We did not observe an interaction of these two
factors, but a larger population may be necessary to observe such
an interactive effect, especially owing to the very small magnitude
of the association. This relationship would need to be explored in
more detail in a population of infants with a normal distribution of
birth weights.
The RICHS cohort represents a relatively healthy sample of
infants born from non-pathologic, low-risk pregnancies, and
therefore is not appropriate for examining certain stressors such
as illicit drug use or maternal smoking. We would encourage the
examination of this gene in appropriate studies that characterize
the effects of these more extreme exposures and conditions to
provide additional insight on the role of placental FKBP5 in
behavioral and mental disorder risk with more extreme stressors.
Our work suggests that there may always be some level of
epigenetic variability in FKBP5 intron 7 present in placenta at the
time of birth, and that this DNA methylation along with genetic
variation have the potential to alter gene expression. The potential
contributors to this variability in methylation remain unclear, but
as RICHS represents a healthy newborn cohort from low risk
pregnancies, it is most likely related to factors and exposures
experienced by the population at large. This assessment has
established predictive value, showing efficacy in predicting motor
outcomes in older infants as quantified through the Bayley
psychomotor developmental index [34] and NNNS scores have
been shown to prospectively relate to medical and behavioral
problems at 4K years of age [35]. In addition, NNNS scores have
been correlated with changes in brain physiology as quantified
through MRI [43] [44].
This large study is the only one, to our knowledge, that has
associated FKBP5 placental methylation with neurobehavioral
outcomes. We have observed associations between genetic
variation and methylation, which both have been previously
shown to contribute to cortisol reactivity [20]. We observed
associations between these epigenetic changes and genetic
variability with altered neurodevelopment, which is important
because it reveals a potential novel role for FKBP5 within the
placenta. However, we are limited in the scope of which we can
study the functional consequences of placental methylation. The
placenta is a transient and dynamic tissue throughout development
and is a relevant biomarker of the fetal environment, and tissue
collected at term represents the end of this process. Placental gene
expression and methylation change over the course of fetal
development [10], thus the changes we observed may not be
reflective of methylation in early development. FKBP5 has been
shown to be expressed within the placenta [33], but it is unclear
from these results which specific cell type expresses FKBP5 within
the placental tissue. The results presented may be confounded by
the heterogeneity of placental tissue we have gathered as the
epigenetic changes that occur here may be occurring in a specific
subset of placental cells. This, in fact, may explain the relatively
small differences in methylation observed between groups. It may
be possible to adjust for cellular proportions in more large scale
methylation data, although this has only been done in limited data
sets [45]. The correlation between methylation and expression in
these infants is moderate (r =20.22), but this level of correlation is
expected as there is significant variability in the measurement of
expression in the placenta, even given our relatively rigorous
collection conditions. The type of and length of delivery time as
well as other uncontrollable clinical factors could be affecting
mRNA stability and thus expression, while DNA methylation is
profoundly more stable, and is thus a more attractive biomarker
for these studies.
Little is known of the function of FKBP5 within the placenta,
and we can only make assumptions based on its role in other
tissues. Animal studies have revealed that blood DNA methylation
of FKBP5 can be used as a surrogate marker of corticosteroid
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induced changes to FKBP5 methylation in the hippocampus [21],
although there have been no animal studies examining these
correlations in placenta and brain, nor have these been
demonstrated in human studies. We have previously observed
that there is a great deal of variability in methylation by tissue and
by gene within a tissue comparing infant cord blood, placenta and
saliva, which are common biomarkers collected during early
infancy [46], and so we would caution interpreting our results as
directly reflecting the state of the hippocampus. However, we
believe the placenta represents a functional tissue for cortisol
regulation and can therefore influence neurodevelopmental
programming. We encourage further analysis of the function of
FKBP5 within the placenta to better understand this process, as
well as work in model systems to understand the relationship
between placental and brain FKBP5.
In our study design, we sought to observe associations between
infant neurobehavior, methylation and expression, which involved
testing multiple hypotheses and so there is a risk of Type I error,
although we limited our analysis to the 6 most sensitive NNNS
scores with the most predictive value. As the RICHS population
represents newborn infants, little long term follow up data is
available at the current time, and our analysis of infant behavior
rests on the NNNS assessment, although the prospective validity of
these assessments has been established [35,47]. This assessment is
highly robust and reliable measure of newborn neurobehavior and
our assessment within the first few days of life removes the
confounding variable of the postnatal environment.
Maternal cortisol has been shown to alter placental CRH,
altering in utero cortisol exposure and the development of the fetal
HPA axis through epigenetic mechanisms [48]. Cortisol has been
shown to induce demethylation of FKBP5 in neuronal progenitor
cells [20], and we hypothesize that increased maternal cortisol may
result in decreased FKBP5 methylation, altering this stress
response axis. We encourage further research (1) to determine
the influence of maternal cortisol on fetal and placental FKBP5
methylation, (2) to characterize how this methylation alters FKBP5
gene and protein expression and subsequent cortisol response over
the course of gestation and (3) to validate our findings in additional
cohorts and to expand this study in a population of more at risk
infants. It would be useful to specifically test infant cortisol
reactivity as a direct measure of physiologic programming. We
provide an impetus for future work to study the physiology of
FKBP5 protein in placental cortisol response and its potential
long-term impact on child neurobehavioral development. Epige-
netic regulation of FKBP5 and other genes involved in placental
cortisol response has been associated with a number of neurolog-
ical outcomes individually, but the interactions between methyl-
ation patterning of these genes and their influence on cortisol
response and neurobehavioral outcomes remains unclear. More
sophisticated analysis of the contribution of cortisol response genes
to placental cortisol response may further elucidate the contribu-
tion of placental epigenetic regulation to neurodevelopmental
outcomes.
Materials and Methods
Study Population
The infants involved in this analysis represent all infants
enrolled in the Rhode Island Child Health Study (RICHS) from
September 2010 until February 2013 with neurodevelopmental
assessments. RICHS recruits mother-infant pairs from Women
and Infants Hospital of Rhode Island [17]. Infants considered
LGA (large for gestational age) and SGA (small for gestational age)
were selected and AGA (adequate for gestational age) infants
matched on sex, gestational age (63 days), and maternal age (62
years) were also enrolled. Exclusion criteria included maternal life-
threatening conditions or age ,18 years and infant congenital or
chromosomal abnormalities. Anthropometric and clinical data was
collected from the inpatient medical record from delivery, and
information about lifestyle, demographics, and exposure histories
was obtained through an interviewer-administered questionnaire.
Newborn neurobehavior was assessed via the NNNS, administered
by certified psychometrists after the first 24 hours of life, but prior
to discharge. Individual components of the NNNS were compiled
into a series of 13 summary scores [49]. In this study, we focused
on the summary scores (habituation, attention, stress-abstinence,
quality of movement, handling and arousal) found to be most
sensitive in prior studies [34,35]. All patients provided written
informed consent for participation under protocols approved by
the institutional review boards at Women and Infants Hospital and
Dartmouth College.
Sample Collection, DNA extraction and bisulfite
modification
For each subject, 12 samples of placental parenchyma (totaling
approximately 10 grams of tissue) from standardized points 2 cm
from the umbilical cord insertion site were excised from the fetal
portion of the placenta, free of maternal decidua. Samples were
placed immediately in RNAlater (Life Technologies) and stored at
4uC. At least 72 hours later, samples were removed from
RNAlater, blotted dry, snap frozen in liquid nitrogen, pulverized
to powder using a liquid nitrogen cooled stainless steel mortar and
pestle (Cellcrusher), and stored at 280uC. DNA was extracted
using the DNeasy Blood & Tissue Kit (Qiagen) and was quantified
using the Nanodrop ND-2000 spectrophotometer (Thermo Fisher
Scientific Inc.). 500 ng of DNA from each sample was bisulfite
modified using the EZ-DNA methylation plate kit (Zymo
Research) and stored at 220uC before analysis. All procedures
were performed following manufacturer’s instructions.
Bisulfite Pyrosequencing and DNA Methylation Analysis
All samples (N= 509) were sequenced for FKBP5 intronic
methylation. FKBP5 intron 7 (GRCh37/hg19 Chr 6:
35,558,486–35,558,567) was amplified with a pyromark PCR kit
(Qiagen) using primers (FKBP5-F, 59- GGATTTGTAGTTGG-
GATAATAATTTGG -39; and 59–biotin- TCTTACCTCCAA-
CACTACTACTAAAA -30) and the following cycling conditions:
95uC for 9 minutes, followed by 42 cycles of 95uC for 30 seconds,
59uC for 1 minute and 72uC for 1 minute, and a final extension
step of 5 minutes at 72uC. PCR products were sequenced using a
PyroMark MD system (Qiagen), and the sequencing primer
FKBP5 SEQ 59- GGAGTTATAGTGTAGGTTT -39. Each
sequencing run contained no template and genomic DNA
negative controls, as well as a methylated and unmethylated
controls (Epitect). A bisulfite conversion control within the assay
sequence was used to assess conversion efficiency.
Genotyping
All samples (N= 509) were genotyped for the SNP rs1360780
through an allelic discrimination assay using predesigned Taqman
primers (part #C___8852038_10, Life Technologies) and Taq-
man universal master mix (Life Technologies) using established
protocols as directed by the manufacturer on a Bio-Rad CFX
connect.
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Gene expression analysis
RNA was isolated from a subset of 21 randomly selected
placentas from each genotype, for a total N of 63. Using the
Qiagen RNeasy kit, RNA concentrations were quantified using
ND-2000 spectrophotometer (Nanodrop), and RNA was stored at
280uC. For every sample, duplicate cDNAs as well as a non-
template control were generated from 100 ng of mRNA using
iScript cDNA master mix (BioRad) following manufacturer
protocol and the resulting cDNA was stored at 4uC. mRNA was
quantified using droplet digital PCR (ddPCR). Each cDNA was
amplified in two technical replicates in different PCR reactions.
Taqman gene expression arrays for the referent gene succinate
dehydrogenase complex, subunit A (SDHA)[50] (part
#Hs00188166_m1) and FKBP5 (part #Hs01561004_m1, Life
Technologies) were utilized. Droplets were generated using the
QX100 droplet generator, amplified using standard conditions for
the assays. Following amplification the droplets were quantified
using the Biorad QX100 droplet reader using Quantasoft software
(version 1.3.20). The relative amount of FKBP5 was defined as the
average FKBP5 absolute counts divided by the average SDHA
absolute counts from 4 replicates. The mean of the CC genotype
was set as the reference and the expression data was divided by this
mean to calculate the relative gene expression by genotype.
Statistical Analysis
Two CpGs (Chr 6: 35558488 and 35558514) were sequenced
based on a previous study [20]. Methylation was defined as the
mean of these two CpG sites, and this data conformed to the
normality assumption. Bivariate associations between methylation
and NNNS scores were assessed with Pearson’s correlations.
Student’s T-test or ANOVA were used to examine relationships
between methylation and categorical variables, including geno-
type. Generalized linear mixed models (GLMMs) adjusted for
birth weight group, maternal age, rs1360780 genotype, and a
random effect variable for conversion plate to account for
variations in conversion plate efficiency were created to explore
the relationship between methylation, genotype, and 6 infant
NNNS outcomes as continuous variables (habituation, attention,
stress-abstinence, quality of movement, handling, and self-regula-
tion) found to be most sensitive in prior studies [34][35]. To
improve interpretability, logistic GLMMS were used to model the
relationship between methylation quartile and membership in the
95th percentile of arousal and stress abstinence scores, based on the
normative percentiles of Fink et al [36]. This model controlled for
birth weight group, maternal age, rs1360780 genotype, and
included a random effect variable for conversion plate to account
for variations in conversion plate efficiency. GLMMs were fit using
the R package NLME and LME4. All data was analyzed in R
version 3.0.2[51].
Supporting Information
Table S1 Compiled methylation, genotype, and gene
expression data with clinical covariates used for analy-
sis, using de identified infant ID numbers.
(XLSX)
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